厄贝沙坦与氢氯噻嗪联用在肾性高血压大鼠体内药动学-药效学关系研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (3): 294-301.

厄贝沙坦与氢氯噻嗪联用在肾性高血压大鼠体内药动学-药效学关系研究

黄晓晖¹, 黄继汉², 陈纭¹, 裘福荣³, 李俊¹, 孙瑞元⁴

¹安徽医科大学药学院,合肥 230032,安徽;
²上海中医药大学药物临床研究中心,上海 201203;
³上海中医药大学附属曙光医院药代动力学实验室, 上海 201203;
⁴安徽省药物临床评价中心, 芜湖 241001,安徽

收稿日期:2012-01-15 修回日期:2012-02-20 出版日期:2012-03-26 发布日期:2012-04-20
作者简介:黄晓晖,男,博士,副教授,硕士生导师,研究方向:定量药理学和临床药代动力学。Tel: 13855183138, E-mail: mathdrug@sina.com
基金资助:
安徽省优秀青年科技基金(08040106813)

Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive rats

HUANG Xiao-hui¹, HUANG Ji-han², CHEN Yun¹, QIU Fu-rong³, LI Jun¹, SUN Rui-yuan⁴

¹School of Pharmacy, Anhui Medical University, Hefei 230032, Anhui, China;
²Center for Drug Clinical Research, Shanghai University of Chinese Medicine, Shanghai 201203, China;
³Pharmacokinetics Laboratory, Shuguang Hospital Attached with Shanghai Chinese Medicine University, Shanghai 201203, China;
⁴Anhui Provincial Center for Drug Clinical Evaluation, Wuhu 241001, Anhui, China

Received:2012-01-15 Revised:2012-02-20 Online:2012-03-26 Published:2012-04-20

摘要/Abstract

摘要： 目的: 应用药动学-药效学结合模型研究厄贝沙坦与氢氯噻嗪联用在肾性高血压大鼠体内单剂量及多剂量用药时的药动学-药效学关系。方法: 将SD大鼠制备成2肾1夹型肾性高血压模型,给大鼠单剂量或多剂量灌胃给药,分别于第1天和第8天连续的预定时间点测定血药浓度,同时测定动脉收缩压(SBP)和动脉舒张压(DBP)等药物效应,建立效应室药动学-药效学结合模型并计算相关的药动学和药效学参数。对单用、联用及单剂量、多剂量的药动学-药效学规律进行定量研究。结果: 厄贝沙坦的药动学特征呈二室模型,氢氯噻嗪在非稳态和稳态条件下均未改变厄贝沙坦的药动学参数,而在稳态条件下,厄贝沙坦可增高氢氯噻嗪的血药浓度及曲线下面积。厄贝沙坦和氢氯噻嗪联用降压效应优于单用的效应。药物效应和效应室浓度之间符合Sigmoid-E_max药效学模型。单剂量下药物效应与血药浓度间存在滞后现象,多剂量下滞后现象消失。E_max、EC₅₀、K_eo等药效学参数在厄贝沙坦组和两药联用组之间的差异有统计学意义。结论: 建立了PK-PD定量数学模型研究厄贝沙坦和氢氯噻嗪联用在大鼠体内单剂量和多剂量用药后药动学-药效学(暴露-反应)关系的规律,并提供了相关的药动学和药效学参数,可为临床合理用药提供参考依据。

关键词: 厄贝沙坦, 氢氯噻嗪, 药代动力学, 药效动力学, 药物相互作用

Abstract: AIM: Pharmacokinetic-pharmacodynamic (PK/PD) modeling was applied to investigate the pharmacokinetic and pharmacodynamic interaction between irbesartan and HCTZ in renal hypertensive rats at non-steady-state and steady-state. METHODS: The renal hypertensive rats were treated with oral irbesartan alone, or HCTZ alone, or the combination of irbesartan and HCTZ for 8 days. Systolic and diastolic blood pressure and plasma concentrations were measured after single- and multi- dosing and PK/PD parameters were analyzed. RESULTS: Irbesartan showed a two-compartment model pharmacokinetic profile. The concentration-time course of irbesartan was not changed by HCTZ, but irbesartan increased the peak plasma concentration and area under the curve of HCTZ at steady-state. Irbesartan plus HCTZ had greater blood pressure lowering action than irbesartan alone. HCTZ increased actions of irbesartan. Hysteresis phenomenon was found between effect and plasma concentrations of irbesartan after a single dose. However, hysteresis phenomenon disappeared at steady state with more rapid realization of maximum concentration and effects. The relationship between effects and effect-compartment concentrations of the drugs was represented by a sigmoid Emax model. CONCLUSION: The results suggest synergistic pharmacodynamic interaction between irbesartan and HCTZ in renal hypertensive rats and some differences of PK/PD properties between irbesartan and irbesartan/HCTZ combinations at non-steady state and steady state. These comparisons are likely to be clinically significant.

Key words: Irbesartan, Hydrochlorothiazide, Pharmacokinetics, Pharmacodynamics, Drug interaction

中图分类号:

R969

黄晓晖, 黄继汉, 陈纭, 裘福荣, 李俊, 孙瑞元. 厄贝沙坦与氢氯噻嗪联用在肾性高血压大鼠体内药动学-药效学关系研究[J]. 中国临床药理学与治疗学, 2012, 17(3): 294-301.

HUANG Xiao-hui, HUANG Ji-han, CHEN Yun, QIU Fu-rong, LI Jun, SUN Rui-yuan. Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 294-301.

参考文献

[1] Girerd X, Rosenbaum D, Aoun J. Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study[J]. Blood Press, 2011,20(S2):22-29.
[2] Vitale C, Marazzi G, Iellamo F, et al. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: The NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study[J]. Int J Cardiol, 2012, 155(2):279-284.
[3] Neutel JM. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review[J]. Postgrad Med, 2011,123(4):126-134.
[4] Greathouse M. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?[J] Congest Heart Fail, 2002, 8(6):313-320.
[5] Mao GG, Chen B, Sun H, et al. Relative bioavailability of irbesartan capsules in healthy volunteers[J]. Chin J Clin Pharmacol, 2001, 17:207-209.
[6] Rane VP, Patil KR, Sangshetti JN, et al. Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations[J]. J Chromatogr Sci,2010, 48(7):595-600.
[7] Maniadakis N, Ekman M, Fragoulakis V, et al. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece[J]. Eur J Health Econ, 2011, 12(3):253-261.
[8] HDavi C, Tronquet G, Miscoria L, et al. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques[J]. Drug Metab Dispos, 2000, 28(1):79-88.
[9] Tutunji LF, Tutunji MF, Alzoubi MI, et al. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: Application to bioequivalence studies[J]. J Pharm Biomed Anal, 2010, 51(4):985-990.
[10] Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers[J]. J Clin Pharmacol, 1998, 38(8):702-707.
[11] Lapuerta P, Franklin S. The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension[J]. J Clin Hypertens, 2009, 11(5):277-283.
[12] Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders[J]. Drugs, 2000, 59(5):1187-1206.
[13] Derosa G, Ferrari I, Cicero AF. Irbesartan and hydrochlorothiazide association in the treatment of hypertension[J]. Curr Vasc Pharmacol,2009, 7(2):120-136.
[14] Chrysant SG, Neutel JM, Ferdinand KC. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial[J]. J Natl Med Assoc, 2009,101(4):300-307.
[15] Huang XH, Qiu FR, Xie HT, et al. Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs[J]. J Cardiovasc Pharmacol, 2005, 46(6):863-869.
[16] 黄晓晖, 裘福荣, 李俊. 厄贝沙坦在健康志愿者体内的药代动力学-药效学结合模型[J]. 中国药理学通报,2005, 21(6): 712-715.
[17] Michael E. Burton. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring[J]. Am J Pharm Educ, 2006, 70(6): 148.
[18] Mager DE, Wyska E, Jusko WJ. Diversity of mehcanism-based pharmacodynamic models[J]. Drug Metab Dispos, 2003, 31(5):510-519.
[19] Sowinski KM. Basic pharmacokinetics and pharmacodynamics: An integrated textbook and computer simulations[J]. Wiley, 2010,21(3):300-356.
[20] 黄晓晖, 史军, 李俊, 等. 药代动力学和药效动力学中数学建模与模拟的基本原理(1)[J]. 中国临床药理学与治疗学,2007, 12(1): 82-89.
[21] Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic(PK/PD) modelling[J]. Int J Clin Pharmacol Ther, 1997, 35(10):401-413.
[22] Shi SJ, Chen H, Gu SF, et al. Pharmacokinetic-pharmacodynamic modeling of daurisoline and dauricine in beagle dogs[J]. Acta Pharmacol Sin, 2003, 24(10):1011-1015.
[23] 黄晓晖, 史军, 李俊, 等. 药代动力学和药效动力学中数学建模与模拟的基本原理(2)[J]. 中国临床药理学与治疗学,2007, 12(3): 334-341.